Loading...
Market
What will be the primary endpoint result of J&J's ongoing studies on new prophylactic strategies for Rybrevant by March 31, 2025?
2
Resolution / Starting Odds
Significant reduction in reactions • 25%
Moderate reduction in reactions • 25%
No significant change • 25%
Increase in reactions • 25%
Johnson & Johnson official press release or peer-reviewed publication
Story
J&J: Dexamethasone Reduces Infusion Reactions in Lung Cancer Patients by 22.5%
Sep 10, 2024, 09:19 PM
Johnson & Johnson ($JNJ) has announced that dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous Rybrevant (amivantamab-vmjw). The prophylaxis regimen with 8 mg dexamethasone taken for two days prior to the first infusion met the primary endpoint of incidence of infusion-related reactions at C1D1. Ongoing studies are evaluating additional prophylactic strategies to further reduce these reactions. The pre-medication regimen showed an infusion-related reaction rate of 22.5% with intravenous Rybrevant.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 40% • 25%
40% to 49% • 25%
50% to 59% • 25%
60% or more • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Increase by more than 10% • 25%
Increase by 5% to 10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Yes • 50%
No • 50%
